{"name":"Adherex Technologies, Inc.","slug":"adherex-technologies-inc","ticker":"","exchange":"","domain":"","description":"Adherex Technologies, Inc. is a biotechnology company focused on developing innovative treatments for cancer. Despite facing financial challenges, the company continues to advance its pipeline with several drugs in early-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":44642000,"revenueGrowth":-6.1,"grossMargin":0,"rdSpend":250000,"netIncome":-9741000,"cash":70551000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ADH -1 and capecitabine","genericName":"ADH -1 and capecitabine","slug":"adh-1-and-capecitabine","indication":"Breast cancer","status":"phase_1"},{"name":"ADH -1 and carboplatin","genericName":"ADH -1 and carboplatin","slug":"adh-1-and-carboplatin","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"ADH -1 and docetaxel","genericName":"ADH -1 and docetaxel","slug":"adh-1-and-docetaxel","indication":"Non-small cell lung cancer","status":"phase_1"}]}],"pipeline":[{"name":"ADH -1 and capecitabine","genericName":"ADH -1 and capecitabine","slug":"adh-1-and-capecitabine","phase":"phase_1","mechanism":"ADH-1 is a vasopressin receptor antagonist, and capecitabine is a thymidylate synthase inhibitor.","indications":["Breast cancer","Colorectal cancer"],"catalyst":""},{"name":"ADH -1 and carboplatin","genericName":"ADH -1 and carboplatin","slug":"adh-1-and-carboplatin","phase":"phase_1","mechanism":"Antiangiogenic and platinum-based chemotherapy","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"ADH -1 and docetaxel","genericName":"ADH -1 and docetaxel","slug":"adh-1-and-docetaxel","phase":"phase_1","mechanism":"ADH-1 is an angiostatic peptide that inhibits angiogenesis by binding to heparin sulfate proteoglycans on the surface of endothelial cells, while docetaxel is a microtubule inhibitor that blocks cell division.","indications":["Non-small cell lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNRTlqUE5sWHpPNm1CcFhQYzMxUHNLd1dGUXBIS3M0U2wtQ3BZUksycXlGRUw5eEdBVFlYc09Qckd1RWZQOG1tU196NDBTaDU1bllZQVE2Sk53VjFoaHBhd3F5VDU0R1kyQTRBaTJPSS1oWld0MWVKRm14VWdBd2g2eGtEVnNDVmdORzVndXJ3WnYyMWxwblA3R21hNnA3bFdOLVl2NmlVcVV5eWhYS2w2S0lFTlctU21JV2R1Um5MV1pBMnR0?oc=5","date":"2026-04-02","type":"pipeline","source":"MarketBeat","summary":"Adherex Technologies (NASDAQ:FENC) Director Rosty Raykov Sells 10,946 Shares - MarketBeat","headline":"Adherex Technologies (NASDAQ:FENC) Director Rosty Raykov Sells 10,946 Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPQTVkODUydGxTX0ZZYzZ3OXB0Z2tKZlFRT3l6a3hOVkNva2Z4VkRZWU1YTUJ6QVpxSW1SUFA3YkhyS2VzVDQwaFlUM3F5R2ZOcHRTUjBUZ1NjUnZtcVFFUnBCakFicEdqQ3pQbHBpOEtKTjIxcXVfQmU5SXBsSXk1cjlJVzhKU1hEVk85aHp5YUtUREtQd0ZLb0otMmZtYVliUFJCNnNseGNSS0VINDlGSjgyNUoyVVZ2SU9LNnFwYkVjNlItbDRVYXp6UWtqekpQTmV1cVJ1NnlvS3BNRnc?oc=5","date":"2026-04-01","type":"deal","source":"MarketBeat","summary":"Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of \"Moderate Buy\" from Brokerages - MarketBeat","headline":"Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of \"Moderate Buy\" from Brokerages","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPME9Melp6TTJjY0F2X0xBdUFpRFkxU25RVE1Zekl0NllZMDNQdUY4MGlDY0I3bVYzci1uQlhMeGdHOFZtV21QZWJzQkYzY2lpMm8xd1lCZUlDWVBtejE5dl9wQ2VlbzdMZkVrNHpXY2RneW5iNjJ4RlRIUnlxekNudFhoa3pJUVcwNFRDUm9LUHBqbGJMWkFXNXRNd1VtRGZXTkV1bFJzOGdJN1lIYTVv?oc=5","date":"2026-03-31","type":"earnings","source":"MarketBeat","summary":"HC Wainwright Issues Negative Forecast for FENC Earnings - MarketBeat","headline":"HC Wainwright Issues Negative Forecast for FENC Earnings","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNVXpYbWJxdm8zcm9sNkkwOFhqWjkwYWRXc1Z1aEtRVXFESHdzRXZuYW5MR3ZSeUgtSlZYUHRjVDJ4Z1RfSWNCUUhxd0t2Z3BJRlg3eGprVE1IbXZRVUtLaGhWY0dlR2tUcnFrOWh5QnhmZ2hLNzZiaU1zMWRwV192Q2V6aGs5WFVmU3BGdU44dmpaQWZtSGZFMTc5cW5iSC02UVIwcS1fOVVHY2pkRk43WjluSQ?oc=5","date":"2026-03-28","type":"pipeline","source":"Defense World","summary":"Adherex Technologies (NASDAQ:FENC) Cut to Strong Sell at Zacks Research - Defense World","headline":"Adherex Technologies (NASDAQ:FENC) Cut to Strong Sell at Zacks Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPNWZ6bjZNN1hlRURtdEprTWtXYTRoNkRLeUFOdTRfWDkxcDlOWTNNTndmcUdaTjlVV2JEVVFrd1BmVTRSV19OdnNxTWN2UXlwNWNNVmQyTU40QVRhZl9pYXRPM0hzX0pEajJfU054U045SVRWazRhR0VHYzYwSFhkaWlaSUJNcU9aUENkR1RJZnRseFpwb2JQRVJwUGRONVdObjNRVDBFYldXRU5acE9GeDhPTFoxVjlMZ3VOdm1hbUNoVWNBLXQ2anRBanVmUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"MarketBeat","summary":"Adherex Technologies (NASDAQ:FENC) Lowered to \"Strong Sell\" Rating by Zacks Research - MarketBeat","headline":"Adherex Technologies (NASDAQ:FENC) Lowered to \"Strong Sell\" Rating by Zacks Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOOEwtNDVfOEpJVzlaWG9WWFhKNENSUlVIaDYwak9wdE9nNk9DTV84VWJqcXFGQ0FZak04dkI5VWt6S21oQnVFa1Jqbll3VnNTYWtNMkNvNUptQ2pCWEM3VVFhazVLbXlhS19PQThNblNmOFNialhkMjFqUFNVcXhmRmJaNTBFMXMzUVI4Q0xVNlI?oc=5","date":"2026-03-27","type":"earnings","source":"MarketBeat","summary":"Adherex Technologies Q4 2025 Earnings Call Transcript - MarketBeat","headline":"Adherex Technologies Q4 2025 Earnings Call Transcript","sentiment":"positive"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOc2xTeWluRmVBN3JSblEybjJ0eWVDUURMcWNRRTNZZTFCLXFJT0ZnTWtlUjZuY1Vnamk3eEZkV0JYMDNHNVloSHNLXzRza3N6ZG5LQVZnNzh1RnZsVHVxUHhITHVIa3hSQWdtU0ZhdlJCSGJXUTJ0MTBzaVRlaHdZSUlvTUxCRWpBQjExSFliM2FzS0xTaEYxNHdadXN0UW44dG9fZQ?oc=5","date":"2026-03-24","type":"earnings","source":"MarketBeat","summary":"Adherex Technologies Q4 Earnings Call Highlights - MarketBeat","headline":"Adherex Technologies Q4 Earnings Call Highlights","sentiment":"positive"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZC1YRF9RLVl2OUV0d3VXMzdWb0pXSXBFeXdTTXM4OVgzQUJvOFM3Y1p0VjJUMGttNTRpZi1pTTN2SGQ0b1F2UXYtQjZlek1FWXh1eWhvN2hBUE5yWlBVYTd5MUptUGRpeE9kZkFRYVo0dm50b0M0T0FJWnJlTGNmaHlPT2pFRWFpOVNTc1d1cml6V3NSeVBiazU2eG9nQlFlbnh5WHpaY1ZfUQ?oc=5","date":"2026-03-14","type":"deal","source":"Defense World","summary":"Adherex Technologies (NASDAQ:FENC) Cut to Buy at Wall Street Zen - Defense World","headline":"Adherex Technologies (NASDAQ:FENC) Cut to Buy at Wall Street Zen","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPeVJVc3ZNYWZBRk9VdnV1dnVaODNjWmVaNFR3X3pNUTRYRkJPTGNLWVlNT0Fvd0NCem9ENUVKdWNKMzNyVWg1ZVJCN244YklRWkVWUkZzR2R4SGVyWHVobmN5cnlNSlRKSVJtWlZZM2ZqbWtfWTJBaF9xcmJ0aF9vb1VRQ05fVUUxVXV1UG5WdzA?oc=5","date":"2024-08-13","type":"earnings","source":"MarketBeat","summary":"Adherex Technologies Q2 2024 Earnings Call Transcript - MarketBeat","headline":"Adherex Technologies Q2 2024 Earnings Call Transcript","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":44642000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":44642000,"period":"2025-12-31"},{"value":47538000,"period":"2024-12-31"},{"value":47538000,"period":"2024-12-31"},{"value":21252000,"period":"2023-12-31"},{"value":21252000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":250000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-9741000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":70551000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}